| Literature DB >> 32346338 |
Ali Alkaladi1, Mohamed Afifi2,3,4, Haytham Ali2,3, Salina Saddick5.
Abstract
This study was carried out to determine the biochemical and molecular potential effects of Zn-ONPs sub-lethal toxicity on the hormonal profile of Oreochromis niloticus (O. niloticus). One hundred and fifty O. niloticus juvenile female were used in this experiment; Ninety for determination of LC50 and other 60 fish were divided into 3 groups with 20 fish each (two replicate in each group). Group I used as control group whereas other groups treated with 1/20 and 1/30 of LC50 respectively for 4 days. Serum, pituitary gland, hepatic, pancreatic and muscular tissues were obtained for hormonal and molecular evaluation. Serum growth hormone (GH), thyroid stimulating hormone (TSH), triiodothyronine (T3), tetraiodothyronine (T4), follicular stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), testosterone and insulin hormones were significantly decreased with a significant increase in both Adrenocorticosteroid hormone (ACTH) and cortisol levels with no change in serum glucagon levels. On molecular levels there were a significant down regulation in transcriptional levels of GH, Insulin like growth factor I (IGF-I), insulin and Insulin receptor-A (IRA genes. These results suggested that, hormonal and molecular alterations can be used as an early biomarkers for Zn-ONPs toxicity in fish.Entities:
Keywords: Growth hormone; Hormonal alterations; Insulin like growth factor I; Testosterone; Zinc oxide nanoparticles
Year: 2020 PMID: 32346338 PMCID: PMC7182787 DOI: 10.1016/j.sjbs.2020.01.010
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 1319-562X Impact factor: 4.219
LC50 of ZnONPs on O. niloticus.
| Fish Groups | Fish No. | Concentration of ZnONPs. µg/l | No. of dead fish after 96 h | a | b | a X b | Σ (a × b) |
|---|---|---|---|---|---|---|---|
| 1 | 10 | Zero | Zero | Zero | Zero | Zero | |
| 2 | 10 | 1 | 1 | 1 | 0.5 | 0.5 | |
| 3 | 10 | 2 | 2 | 1 | 1.5 | 1.5 | |
| 4 | 10 | 3 | 3 | 1 | 2 | 2.5 | |
| 5 | 10 | 4 | 5 | 1 | 4 | 4 | |
| 6 | 10 | 5 | 6 | 1 | 5.5 | 5.5 | |
| 7 | 10 | 6 | 8 | 1 | 7 | 7 | |
| 8 | 10 | 7 | 9 | 1 | 8.5 | 8.5 | |
| 9 | 10 | 8 | 10 | 1 | 9.5 | 9.5 | |
| 39 |
a = Constant factor between two successive doses, b = The mean of dead fish in the groups.
n = Number of fish in each group Σ = The sum of (a × b).
96 LC50 = highest dose - Σ (a × b)/n.
8–39/10 = 8–3.9 = 4.1 µg/l.
Primer sequences and PCR conditions.
| Gene | Primer sequence (5′→3′) | Gene accession number | Annealing temp °C/cycles | References |
|---|---|---|---|---|
| GH | CTGTCTGTCTGTCTGTCAGTCGT | M26916.1 | 60 °C/40 cycle | |
| IGF-1 | CCCGAACTTCCTCGACTTGA | EU272149 | 60 °C/40 cycle | |
| Insulin | ACAACCCCAGGAGAGATGTG | XM_003458679.5 | 56 °C/50 cycle | |
| IRA | AGACGGTGAACGAGTCGGCC | KC517071.1 | 65 °C/50 cycle | |
| β-actin | ACCCACACAGTGCCCATC | EU887951 | 60 °C/40 cycle |
GH, Growth hormon; IGF-I, Insulin like growth factor I; IRA, Insulin receptor-A.
Effect ZnONPs sub-lethal concentrations on some hormone of Oreochromis niloticus.
| Group I (control group) | Group II (1/2 LC50) | Group III (1/3 LC50) | |
|---|---|---|---|
| GH (pg/ml) | 667.4 ± 29.08a | 398 ± 24.2c | 546 ± 26.9b |
| TSH (μIU/ml) | 2.38 ± 0.043a | 1.05 ± 0.02c | 1.8 ± 0.08b |
| ACTH (pg/ml) | 172.8 ± 18.6c | 284.3 ± 6.3a | 205.3 ± 11.3b |
| FSH (mIU/ml) | 4.2 ± 0.85a | 1.1 ± 0.13c | 3.1 ± 0.43b |
| LH (mIU/ml) | 19.6 ± 2.15a | 9.4 ± 1.02c | 13.7 ± 1.32b |
| T3 (pg/mL) | 375.9 ± 32.6a | 186.8 ± 26.8c | 246.3 ± 29.4b |
| T4 (ng/mL) | 168.4 ± 17.4a | 48.6 ± 8.2c | 96.8 ± 13.8b |
| Cortisol (μg/ml) | 5.48 ± 0.67c | 12.25 ± 1.2a | 8.9 ± 0.98b |
| Estradiol (pg/ml) | 32.6 ± 2.31a | 19.4 ± 1.42c | 25.7 ± 1.85b |
| Testosterone (ng/ml) | 6.28 ± 1.12a | 2.25 ± 0.82c | 4.3 ± 0.42b |
| Insulin (µIU/ml) | 5.68 ± 0.88a | 2.15 ± 0.62c | 4.26 ± 0.36b |
| Glucagon (mU/L) | 4.42 ± 0.63a | 4.63 ± 0.44a | 4.83 ± 0.64a |
Means carrying different superscripts are significant at P < 0.05.
Fig. 1The relative gene expression of Growth hormon (GH) A, IGF-I: Insulin like growth factor I (IGF-I) B, Insulin, C and Insulin receptor (IRA) D.